Pharmaceutical - isavuconazole


Current filters:


Popular Filters

Astellas' isavuconazole NDA accepted by US FDA

Astellas' isavuconazole NDA accepted by US FDA


The US Food and Drug Administration has accepted a New Drug Application filing by Japanese drug major…

Astellas PharmaFungal diseasesInvasive aspergillosisInvasive mucormycosisisavuconazoleOncologyPharmaceuticalRegulationUSA

Astellas amends license deal for isavuconazole with Basilea


Japanese drug major Astellas Pharma has amended the license, co-development and co-promotion agreement…

Antibiotics and Infectious diseasesAstellas PharmaBasilea PharmaceuticaCanadaisavuconazoleLicensingNorth AmericaPharmaceuticalUSA

Astellas’ antifungal study reports positive results


Astellas Pharma has announced positive topline data from the Phase III invasive aspergillosis study (SECURE)…

Asia-PacificAstellas PharmaBasilea PharmaceuticaDermatologicalsisavuconazolePharmaceuticalResearch

Basilea updates on isavuconazole development


Switzerland-based Basilea Pharmaceutica Ltd. (SIX: BSLN) provided an update today (July 17) on the Phase…

Antibiotics and Infectious diseasesAstellas PharmaBasilea PharmaceuticaisavuconazolePharmaceuticalResearch

GlaxoSmithKline gets global rights to Basilea's Toctino


UK pharma giant GlaxoSmithKline (LSE: GSK) says that its dermatology-focussed subsidiary Stiefel has…

Basilea PharmaceuticaceftobiproleDermatologicalsGlaxoSmithKlineisavuconazoleLicensingPharmaceuticalResearchStiefelToctino

Back to top